The Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program

Thomson Reuters ONE

The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 26 April 2013 resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive program resolved by the annual general meeting - on a directed share issue of no more than 754,912 redeemable and convertible class C shares.

The general meeting also resolved to authorize the board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorization may be made on one or several occasions until the annual general meeting in 2014 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share (approximately SEK 0.55).

The board of directors has resolved to exercise the repurchase authorization for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 19 September - 29 September 2013.

The company currently holds 4,408,260 own class C shares. Subsequently to the effected repurchase of class C shares above, the number of own class C shares will amount to 5,163,172.

The class C shares will, following the repurchase, be converted to common shares in the number that is required to ensure delivery under the incentive program.

---


About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (SOBI.ST) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com


For more information - not for publication

Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 410 71 80 T: +46 8 697 20 00
oskar.bosson@sobi.com jorgen.winroth@sobi.com


The information was released for public distribution on 13 September 2013 at 08:00 CET.

The Board of Directors exercises authorization for repurchase


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

HUG#1729034